DNA

#3010
Ginkgo Bioworks Holdings, Inc.
7.7250 USD
+16.34%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
7.5600
7.7400
Range Annuel
5.3700
9.7200
Changement quotidien
+16.34%
Changement Mensuel
+10.36%
Evolution sur 6 mois
-13.01%
Changement Annuel
-13.01%
Clôture Précédente
6.6400
Open
7.5600
Bid
Ask
Low
7.5600
High
7.7400
Volume
495
Open full chart

Financials

Overview Relevé Statistics
Quarterly Annual
  • Market Capitalization 455.1906 M
  • Employee 485
  • Founded 2008
  • CEO Jason Kelly
  • Website www.ginkgobioworks.com
  • Headquarter Delaware, United States
  • FIGI BBG00YPS1KY3
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-1.47
Price to sales ratio
2.71

Ginkgo Bioworks Holdings Inc Class A

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.

Nouvelles